SANDRA CAYLER: Open Payments
NPI 1003466921 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$366 in 17 payments from 11 companies in 2025. Trend: 2023 $104 · 2024 $205 · 2025 $366
Food & beverage: $366
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 3 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $22 |
| Neos Therapeutics, LP | 1 | $20 |
| Tris Pharma Inc | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
Products named: FANAPT, CAPLYTA, TRINTELLIX, REXULTI, Auvelity, HETLIOZ, SPRAVATO, Quviviq.
Industry payments across NE — which companies pay providers there.
